HOUSE_OVERSIGHT_028419.jpg

dentifier":" anf-body- 31", "inlineTextStyles": [{"range":{"lengt im}, {"range":{"Llength":226, "start":0},"t body", "role": "body", "text":"In 2000, the that it had evidence the company was imp cancers as well as to promote a feeling patients.","type™:"text"}, {"identifier"™: 32","inlineTextStyles": [{"range":{"lengt im}, {"range"™":{"Llength":175, "start":0},"t body", "role": "body", "text": "a€ePerhaps more than for any ot to provide and distribute thalidomide re the agency wrote in the letter.", "type": "text "}, {"additions":[{" 16284/000100515001000229/0001005150-01- h":226,"start":0},"textStyle":" anf-ts- extStyle"™:" anf-ts-1"}],"layout"™:"default-— agency issued a formal warning letter, saying roperly marketing Thalomid for a variety of of a€egeneral well-beinga&€ in cancer "_anf-body- h":175,"start":0},"textStyle":" anf-ts- extStyle"™:" anf-ts-1"}],"layout":"default-— her available drug, the need sponsibly is essential to the public health, a4€ URL": "https://www.sec.gov/Archives/edgar/data/8 000229.txt", "range": {"length":20,"start":286},"type™:"link"}],"identifier":" anf-body- 33","inlineTextStyles":[{"range":{"length":517, "start":0},"textStyle":" anf-ts- i"},{"range"™:{"length":517,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"Over the next few years, however, Mr. Hugin and other top xecutives repeatedly referred to Thalomid 4€" and later Revlimid 4€" as the key to Celgenea€™s financial future, even thoug the drugs to treat certain cancers until that 92 percent of Thalomidad€™s prescrip at an investor conference in 2004, Mr. H is the financial engine that drives us.4 34", "inlineTextStyles": [{"range":{"lengt i"},{"range"™:{"Llength":171,"start":0},"t body", "role": "body", "text":"Celgene has saying it settled the lawsuit in 2017 to of protracted litigation.ad€", "type": "tex 35", "“anlineTextstyles": [{"range":{"léengt 1"},{"range":{"Length":186, "start":0},"t h it would not get formal approval to market 2005 and 2006. In 2001, the company reported tions were being written to treat cancer, and ugin said, a€eThalomid is important, because it €", "type"™:"text"}, {"identifier":" anf-body- h":171,"start":0},"textStyle":" anf-ts- extsStyle"™:" anf-ts-1"}],"layout"™:"default- denied that it engaged in illegal marketing, avoid the uncertainty, distraction and expense t"}, {"identifier":" anf-body- body", "role": "body", "text": "The incredib promising treatments for multiple myelom patients a year, was a windfall for Celgene.", "type": "text"}, {"additions": [{ s/revlimid-long- form.pdi", "range": {"length":17,"start":2 36", "inlineTextStyles": [{"range": {"lengt 1"},{"range":{"length":218, "start":0},"t body", "role":"body", "text":"Introduced t Revlimid, a closely related derivative o 2017, Celegene had raised the price of a $16,000.","type"™:"text™},{"identifier"™:" 3","layout":"heading4" drug makers", "type": "text"}, {"identifier 37", "inlineTextStyles": [{"range":{"lengt i"},{"range":{"Length":328,"start":0},"t body", "role":"body", "text":"The company ,"role":"heading4", h":186,"start":0},"textStyle":" anf-ts- extStyle"™:" anf-ts-1"}],"layout":"default- le demand for Thalomid, and later Revlimid, as a, a disease that affects more than 30,000 "URL": "https://media.celgene.com/content/upload O00}, "type™:"link"}],"identifier":" anf-body- h":218,"start":0},"textStyle":" anf-ts- extsStyle"™:" anf-ts-1"}],"layout":"default- o the market in 2006, a monthda€™s supply of f thalidomide, initially cost about $6,000. By monthae€™s supply to more than anf-heading4- "text":"A brutal battle to fend off generic ":" anf-body- h":328,"start":0},"textStyle":" anf-ts- extsStyle"™:" anf-ts-1"}],"layout"™:"default- was able to aggressively raise prices in part as a result of its legal monopoly. Under can exclusively market a drug for up to with any patents, the market opens to ge precipitously.", "type": "text"}, {"identift 38", "inlineTextStyles": [{"range":{"leng im}, {"range":{"Llength":113, "star 0}," body", "role": "body", "text":"To protect mounted an aggressive campaign to exten monopoly.", "type": "text"}, {"identifier"™: 39", "inlineTextStyles": [{"range":{"leng 1"},{"range": {"length":269, "start":0}," body", "role": "body", "text": "4€eTheyae™ve drug and to build as many walls around i president for federal government affairs the generic drug industryde™s lobbying g 40", "inlineTextStyles": [{"range":{"lengt i"},{"range"™:{"Llength":145, "start":0},"t wt, federal regulations, a pharmaceutical company seven years. Once that period expires, along neric competition and prices typically fall ier":"_ anf-body- h":113,"start":0},"textStyle":" anf-ts- extStyle"™:" anf-ts-1"}],"layout"™:"default- he profits from Revlimid and Thalomid, Celgene its "_anf-body- h™:269,"start":0},"textStyle":" anf-ts- extStyle"™:" anf-ts-1"}],"layout":"default- gone to pretty great lengths to protect that as they can,a€ said Michael Brzica, the vice t the Association for Accessible Medicines, ","type™:"text"}, {"identifier":" anf-body- a roup Kh" ex 7145,"start":0},"textStyle":" anf-ts- tStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"Celgene has been repeatedly accused of restricting access to samples of its drugs, which generic c ompanies need to test their competing HOUSE_OVERSIGHT_028419